Genflow Biosciences plc has announced a development program in ophthalmology focused on advancing a novel gene therapy leveraging its proprietary centenarian SIRT6 (cSIRT6).

Once again, Pernodet and team realized the answer could lie in the SIRT family, this time SIRT6. This sirtuin regulates two further factors affecting ageing: genome stability, via control of ...